HaemaLogiX Ltd is pleased to announce that the KOALA Phase 1 clinical trial is now active and open to patient enrolment at the Peter MacCallum Cancer Centre. The study targets multiple myeloma, the second most common blood cancer worldwide.
Read article +HaemaLogiX is gearing up for an initial public offering (IPO) this year, hoping that market proceeds can help accelerate a second Phase IIb trial of a monoclonal antibody targeting Kappa myeloma antigen – a largely untouched target in an increasingly competitive multiple myeloma (MM) market.
Read article +The core breakthrough is the discovery of two novel tumour-specific antigens. HaemaLogiX has identified Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) — conformational, lipid-associated epitopes that arise when free light chains bind sphingomyelin within the malignant plasma cell membrane, expressed only on cancerous plasma cells and absent from normal bone marrow plasma cells.
Read article +CSO Dr Rosanne Dunn's writeup on HaemaLogiX's antigen discovery.
Read article +Dr Rosanne Dunn sits down with Dylan Kissane from Labiotech, to talk about HaemaLogiX's next-generation immunotherapies.
Read article +